Parkinson’s disease mortality and years of potential life lost in Iran: A 10-year national analysis (2013–2023)
Open Access
- 1 April 2026
- journal article
- Published by SAGE Publications in Journal of Public Health Research
- Vol. 15 (2)
Abstract
Background: Parkinson’s disease (PD) is a leading neurodegenerative disorder associated with increasing global morbidity and premature mortality. Despite its growing burden, national trends in PD-related mortality and years of potential life lost (YPLL) remain understudied in Iran. Objectives: To examine temporal trends in PD-related mortality and YPLL in Iran from 2013 to 2023 and to assess demographic and regional disparities. Methods: This repeated cross-sectional study used data from the Iranian National Death Registration System. All deaths attributed to PD (ICD-10 codes G20 and G21) between 2013 and 2023 were included. Crude age-specific and cause-specific mortality rates were calculated, and YPLL was estimated using standard methods. Temporal trends were assessed using regression-based analyses. Spatial patterns were evaluated using ArcGIS, and statistical analyses were performed in Stata version 17. Results: A total of 9229 PD-related deaths were recorded. Crude mortality rates increased from 0.21 per 100,000 in 2013 to 1.77 in 2023, while YPLL rose from 1.21 to 7.86 per 100,000. Males consistently exhibited higher mortality and YPLL than females. Geospatial analysis identified higher burdens in Tehran, Khorasan Razavi, Isfahan, and Fars. Lower rates in several rural provinces may partly reflect underreporting or disparities in healthcare access. Conclusion: The observed increase in crude PD-related mortality and YPLL over the past decade suggests a growing public health challenge in Iran. However, these trends should be interpreted with caution, as they may be influenced by population aging, improvements in diagnosis, and changes in death registration practices. Strengthening early diagnosis, specialized care, and equitable access to neurological services—particularly in underserved regions—remains a public health priority.Keywords
Funding Information
- Mashhad University of Medical Sciences (4031152)
This publication has 19 references indexed in Scilit:
- Burden of Parkinson’s disease in Iran: disparities, trends, and the impact of social development indicatorsNeurological Sciences, 2025
- The epidemiology of Parkinson's diseaseThe Lancet, 2024
- Trial of Cinpanemab in Early Parkinson’s DiseaseNew England Journal of Medicine, 2022
- Parkinson Disease Epidemiology, Pathology, Genetics, and PathophysiologyClinics in Geriatric Medicine, 2020
- Pathophysiology and Therapeutic Perspectives of Oxidative Stress and Neurodegenerative Diseases: A Narrative ReviewAdvances in Therapy, 2019
- Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet Neurology, 2019
- Common Myths in the Use of Levodopa in Parkinson DiseaseJAMA Neurology, 2017
- The prevalence of Parkinson's disease: A systematic review and meta‐analysisMovement Disorders, 2014
- Epidemiology and etiology of Parkinson’s disease: a review of the evidenceEuropean Journal of Epidemiology, 2011
- Gender differences in Parkinson's diseaseGender Medicine, 2007